Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development
- PhenoScope can cut drug development time and costs significantly, while delivering safer & more effective therapy for cancer patients
- It can provide more precise patient dosing to reduce side effects, increase efficiency and reduce wastage
CHICAGO, IL & PALO ALTO, CA – 3 April 2024 – SimBioSys, a leading innovator in precision oncology, and General Inception (“GI”), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.
